Imugene Ltd
Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.
See more information about Imugene Ltd
Imugene completes enrolment of first cohort of patients in Phase I clinical trial of checkpoint immunotherapy candidate PD1-Vaxx
Imugene Ltd (ASX:IMU) (OTCMKTS:IUGNF) has completed enrolment of the first cohort of patients in a Phase I clinical trial of its checkpoint immunotherapy candidate, PD1-Vaxx.
The clinical-stage immune-oncology company has enrolled the first three patients in the first low dose PD1-Vaxx cohort with non-small cell lung cancer.
Significant milestone
Imugene managing director and chief executive officer Leslie Chong said: "The start of our study with first patient dosed in Australia just 18 days ago was a significant milestone for Imugene and clinicians treating Australians faced with the challenge of lung cancer.
"I'm encouraged by the speed at which our Australian hospitals have recruited the first cohort of patients."
Three different doses of PD1-Vaxx to be tested
The first-in-human, Phase 1, multi-centre, dose-escalation study of PD1-Vaxx is recruiting patients with non-small cell lung cancer.
Medical investigators will test three different doses of PD1-Vaxx.
The primary goal of the Phase 1 trial is to determine safety and an optimal biological dose as a monotherapy (mOBD).
Efficacy, tolerability and immune response will also be measured.
Other Imugene Ltd news
- Imugene fully funded to progress four clinical trials in the near-term
2020-10-26 - Imugene receives third ethics approval to start phase-1 clinical trial of PD1-Vaxx cancer immunotherapy
2020-08-21 - Imugene research published in prestigious journal titled Frontiers in Immunology
2020-05-28 - Imugene outlines its focus on developing immuno-oncology treatments in half-yearly report
2020-02-28 - Imugene has CheckVacc preclinical data published in the Journal of American College of Surgeons
2020-02-12
